Megalabs Colombia

What Megalabs Colombia does

Megalabs is a privately held, Latin American–origin pharmaceutical company that develops, manufactures, and commercializes therapeutic solutions across prescription and over-the-counter channels. It operates 17 manufacturing plants and 6 coordinated R&D centers across Latin America, with a regional footprint spanning 18-20 countries and a headcount of more than 7,700. The portfolio covers all major therapeutic areas and exceeds 1,800 products, with dermatology sub-brands (Medihealth, Hidrisage) developed at the Colombia Development Center and exported to 18 countries; 14 of the 20 most successful products are own developments rather than licensed in.

The company's technology base centers on a Stage-Gate innovation management process, a Pilot Plant and Analysis Laboratory capable of running 25+ formulation projects per year, and a regional pharmacovigilance system (CIM) that monitors product safety post-market. Regional headquarters sit in Bogotá, Colombia, and a Campus in the Canelones free trade zone in Uruguay houses two manufacturing plants and an R&D center. The Colombia Development Center was recognized by Minciencias in 2020 as an R&D+i Unit.

Megalabs' go-to-market relies on a partner-led model with long-term licensing and co-development relationships (operationalized through a Partnering Colombia program supported by Business Development, R&D, Regulatory, IP, and Legal functions) combined with broad distribution to pharmacies and patients. Revenue mechanics span product sales across ethical and OTC channels plus licensing/co-development income. The 24% doctor-prescription rate and over 1 million monthly prescriptions (per Close Up/IMS 2019) underscore brand reach, though revenue figures are not publicly disclosed.

Name

Megalabs Colombia

Legal name

Megalabs

Website

https://megalabs.com.co

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

Megalabs is a privately held Latin American pharmaceutical company operating 17 manufacturing plants, 6 R&D centers, and a 1,800+ product portfolio across 18-20 countries, serving patients, prescribers, and licensing partners with prescription, OTC, and dermatology brands.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical products
• Prescription medications
• Over-the-counter drugs
• Dermatological products
• Pharmaceutical manufacturing

Headquarters

HQ city

Bogotá

HQ country

Colombia

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of therapeutic solutions, medications, and health products across Latin America. The company develops, manufactures, and commercializes pharmaceutical products through multiple therapeutic areas.
2. Licensing and Co-development: Long-term business relationships with licensors and co-development partnerships for new products and investment opportunities. The company seeks to strengthen its pipeline through alliances and new licenses.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Megalabs Colombia develops, manufactures, and commercializes pharmaceutical products across Latin America, including prescription medications and over-the-counter products spanning all therapeutic areas. The company operates 17 manufacturing plants and 6 R&D centers to produce therapeutic solutions including proprietary dermatological lines such as Medihealth and Hidrisage manufactured in Colombia and exported to 18 Latin American countries. With 325 million units of annual production capacity and a portfolio of 1,800+ products, the company serves both retail consumers and healthcare providers through prescription and OTC distribution channels.

Product overview

Megalabs is a Latin American health and pharmaceutical company operating across 18 countries with 17 production plants and 6 R&D centers. The company develops, manufactures, and commercializes therapeutic solutions including prescription medications and over-the-counter products. Key product lines include Medihealth and Hidrisage (dermatological products developed and manufactured in Colombia), alongside a portfolio of 1,800+ products spanning all therapeutic areas. The company operates with a pharmacovigilance system (CIM) for product safety monitoring and maintains a Stage-Gate innovation process for product development.

Differentiator

Problem solved

Functional benefit

Brands

• Medihealth: Dermatology product line developed by Megalabs Colombia's Centro de Desarrollo, exported to 18 countries in Latin America.
• Hidrisage

Products and services

• Medihealth Dermatological product line developed at the Megalabs Colombia Development Center (Centro de Desarrollo de Megalabs Colombia), manufactured in Colombia and exported to 18 Latin American countries. Targeted at consumer dermatological care through retail pharmacy channels across the region.
• Hidrisage Dermatological product line developed at the Megalabs Colombia Development Center (Centro de Desarrollo de Megalabs Colombia), manufactured in Colombia and exported to 18 Latin American countries. Targeted at consumer dermatological care through retail pharmacy channels across the region.
• Over-the-Counter Products (Productos de Venta Libre) Non-prescription pharmaceutical product category available to consumers through retail pharmacy and consumer outlets across Latin America. Part of the broader 1,800+ product portfolio spanning all therapeutic areas, complemented by the company's prescription pharmaceutical line distributed through healthcare providers.

Quantifiable outcome

• 325 million units production capacity
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature4 records

Partnerships

One partnership is on record.

• Licensors and Licensing PartnerscoreOEM/ Whitelabel/ Licensing PartnerMegalabs establishes long-term business relationships with licensors and licensing partners. The company is in permanent search for new products and investment opportunities through both own developments and new licenses. They maintain a professional management team dedicated to Business Development, Strategic Marketing, R&D, Regulatory Affairs, Intellectual Property, and Legal matters to create value throughout the partnership lifecycle.

Scale indicators10 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• EMS: Major Brazilian generic and branded pharmaceutical manufacturer with growing LatAm presence; comparable in product mix (generics, branded generics, OTC) and emphasis on regional scale manufacturing.
• Eurofarma: Brazil's largest privately held pharmaceutical company with multi-country LatAm operations and broad therapeutic coverage; comparable as a vertically integrated regional pharma with branded generics, own R&D, and pan-LatAm commercial reach.
• Aché Laboratórios: Brazilian pharmaceutical company with diversified portfolio across prescription, OTC, and dermatology; comparable in therapeutic breadth, own R&D, and Latin American commercial footprint.
• Laboratorios Bagó: Argentine pharmaceutical group with multi-country LatAm presence and integrated manufacturing; closely comparable as a regional pharma with proprietary branded generics and own R&D across therapeutic areas.
• Biolab Farmacêutica: Brazilian pharmaceutical company focused on branded generics and specialty therapeutics with international expansion; comparable in branded-generic strategy and LatAm growth orientation.
• Genomma Lab: Mexican-headquartered OTC and personal-care pharmaceutical company with deep distribution across Latin America; directly comparable in product mix (OTC/consumer health), regional commercial model, and growth orientation in LatAm markets.

Broad incumbents

• Teva Pharmaceutical: World's largest generic pharmaceutical manufacturer; broadly comparable as a generic FDF manufacturer with global distribution, but operates at much larger scale and is not LatAm-specialized.
• Sandoz (Novartis): Global generics and biosimilars division of Novartis; comparable in generic FDF manufacturing and broad therapeutic coverage, though with significantly broader global reach than Megalabs.
• Gedeon Richter: Hungarian-headquartered pharmaceutical company with strong generics and biosimilars portfolio across emerging markets; comparable in branded-generic strategy and emerging-markets commercial model, though European-headquartered.

Emerging players

• Aspen Pharmacare: South African specialty and generics pharma with growing emerging-market footprint; comparable as a regional pharma expanding into adjacent emerging markets, though based in a different geography.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/megalabsco

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Megalabs Colombia